Sana Biotechnology Inc
$ 4.23
3.93%
24 Feb - close price
- Market Cap 1,084,110,000 USD
- Current Price $ 4.23
- High / Low $ 4.30 / 4.09
- Stock P/E N/A
- Book Value 0.74
- EPS -0.96
- Next Earning Report 2026-03-16
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -0.96 %
- 52 Week High 6.55
- 52 Week Low 1.26
About
Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington.
Analyst Target Price
$8.71
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-11 | 2025-05-06 | 2025-02-26 | 2024-11-06 | 2024-08-08 | 2024-05-08 | 2024-02-29 | 2023-11-08 | 2023-08-03 | 2023-05-08 | 2023-03-16 |
| Reported EPS | -0.16 | -0.39 | -0.2 | -0.23 | -0.25 | -0.32 | -0.32 | -0.41 | 0.02 | -0.59 | -0.43 | -0.38 |
| Estimated EPS | -0.18 | -0.2 | -0.2 | -0.2428 | -0.27 | -0.28 | -0.32 | -0.38 | -0.45 | -0.43 | -0.45 | -0.51 |
| Surprise | 0.02 | -0.19 | 0 | 0.0128 | 0.02 | -0.04 | 0 | -0.03 | 0.47 | -0.16 | 0.02 | 0.13 |
| Surprise Percentage | 11.1111% | -95% | 0% | 5.2718% | 7.4074% | -14.2857% | 0% | -7.8947% | 104.4444% | -37.2093% | 4.4444% | 25.4902% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-16 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.12 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SANA
2026-02-24 04:56:59
Sana Biotechnology (SANA) has experienced recent share price momentum, exhibiting a 5.71% gain over the past week and a 41.32% one-year total shareholder return, contrasting with a significant five-year loss. Despite trading at a Price-to-Book ratio of 5.6x, indicating a richer valuation than the broader US biotech group, this is lower than a select peer group. The article highlights that while the stock appears valued for its pipeline, investors must consider ongoing net losses and reliance on clinical milestones.
2026-02-23 21:30:26
Sana Biotechnology, Inc. announced it will webcast presentations at two investor conferences in March 2026: the Cowen 46th Annual Health Care Conference on March 2nd and the Citizens Life Sciences Conference on March 11th. The presentations will provide a business overview and updates, with webcasts available on Sana's Investor Relations page. The company focuses on developing engineered cells as medicines.
2026-02-23 21:05:25
Sana Biotechnology, Inc. announced it will present at two investor conferences in March 2026: the Cowen 46th Annual Health Care Conference and the Citizens Life Sciences Conference. The presentations will offer a business overview and an update, with webcasts accessible on the company's Investor Relations page. Sana Biotechnology focuses on developing engineered cells as medicines.
2026-02-22 14:53:23
Despite a record number of biotech IPOs in 2021, the sector's stock performance has been largely negative, prompting experts to caution against going public in the current market. Many preclinical biotechs that went public last year are now trading well below their initial offering prices, with one investor characterizing the period as a bear market. While Nasdaq anticipates continued IPO activity, an industry investor suggests it's "silly, if not suicidal" for companies to consider an IPO right now.
2026-02-19 05:30:59
Sana Biotechnology has appointed Brian Piper as its new Executive Vice President, Chief Financial Officer, Treasurer, and Principal Financial Officer, concluding CEO Steve Harr’s interim role. Piper brings over 25 years of biotech finance experience and his compensation package includes a base salary of $515,000, a target annual bonus, and significant equity awards. The company aims to strengthen its financial leadership as it advances clinical programs in type 1 diabetes and B-cell related diseases.
2026-02-18 18:27:43
This article details recent personnel changes in the Pacific Northwest tech community. Key moves include Sana Biotechnology hiring Brian Piper as CFO, Jeff Lamothe becoming CEO of Aptevo Therapeutics, and Scott Kushino taking the CEO role at Violett. The piece also covers various other leadership and sales appointments across several Seattle-area startups and tech companies.
